Increased mortality in patients with the lupus anticoagulant: The vienna lupus anticoagulant and thrombosis study (LATS)

Blood

Volumn 125, Issue 22, 2015, Pages 3477-3483

  Gebhart, Johanna ^a   Posch, Florian ^a   Koder, Silvia ^a   Perkmann, Thomas ^a   Quehenberger, Peter ^a   Zoghlami, Claudia ^a   Ay, Cihan ^a   Pabinger, Ingrid ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; ANTICOAGULANT AGENT;

ADULT; AGE; ANEURYSM RUPTURE; ANTICOAGULANT THERAPY; ARTERIAL THROMBOEMBOLISM; ARTICLE; AUSTRIAN; AUTOIMMUNE DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAUSE OF DEATH; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEART INFARCTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC CARDIOMYOPATHY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM; ANTIPHOSPHOLIPID SYNDROME; AUSTRIA; BLOOD; CASE CONTROL STUDY; COMPLICATION; FOLLOW UP; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; SURVIVAL; THROMBOSIS;

ADULT; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; AUSTRIA; CASE-CONTROL STUDIES; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; SURVIVAL ANALYSIS; THROMBOSIS;

EID: 84930959464     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-11-611129     Document Type: Article

References (40)

1. de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005;3(9): 1993-1997.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
3. Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev. 2008;7(4):272-277.
4. Male C, Lechner K, Speiser W, Pabinger I. Transient lupus anticoagulants in children: stepwise disappearance of diagnostic features. Thromb Haemost. 2000;83(1):174-175.
5. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med. 1990;20(3): 231-236.
6. Vila P, Hernández MC, López-Fernández MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost. 1994;72(2): 209-213.
7. Du VX, Kelchtermans H, de Groot PG, de Laat B. From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: pathogenic mechanisms of the antiphospholipid syndrome. Thromb Res. 2013;132(3):319-326.
8. Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, Ugalde J, Aguirre C. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus. 2004;13(12): 900-905.
9. Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004;164(1): 77-82.
10. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309-1311.
11. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74(4): 1185-1190.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
13. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11):1271-1277.
14. Pengo V, Tripodi A, Reber G, et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7(10):1737-1740.
15. Wenzel C, Stoiser B, Locker GJ, et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med. 2002;30(4):763-770.
16. Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost. 1987;57(2):144-147.
17. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983; 1(11):710-719.
18. Hakulinen T, Seppä K, Lambert PC. Choosing the relative survival method for cancer survival estimation. Eur J Cancer. 2011;47(14): 2202-2210.
19. Haselboeck J, Ringl H, Mueller C, Pabinger I, Winkler S. Post-surgical hemorrhagic infarction of the adrenal gland as the first clinical manifestation of antiphospholipid syndrome after 43 years of antibody-positivity. Mod Rheumatol. 2013;23(6): 1237-1241.
20. Cervera R, Serrano R, Pons-Estel GJ, et al; on behalf of the Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients [published online ahead of print January 24, 2014]. Ann Rheum Dis.
21. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692-699.
22. Sørensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998; 338(17):1169-1173.
23. Pabinger I, Vossen CY, Lang J, et al. Mortality and inherited thrombophilia: results from the European Prospective Cohort on Thrombophilia. J Thromb Haemost. 2012;10(2):217-222.
24. Reitter S, Laczkovics C, Waldhoer T, Mayerhofer M, Vutuc C, Pabinger I. Long-term survival after venous thromboembolism: a retrospective selected cohort study among young women. Haematologica. 2010;95(8):1425-1428.
25. Reitter SE, Waldhoer T, Mayerhofer M, et al. Long-term survival of patients with a history of venous thromboembolism. Ann Hematol. 2011; 90(5):585-594.
26. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827-1832.
27. Urbanus RT, de Groot PG. Antiphospholipid antibodies-we are not quite there yet. Blood Rev. 2011;25(2):97-106.
28. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332(15):993-997.
29. Muñoz-Rodriguez FJ, Font J, Cervera R, et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum. 1999;29(3):182-190.
30. Arnaud L, Mathian A, Ruffatti A, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2014;13(3):281-291.
31. Pengo V, Ruiz-Irastorza G, Denas G, Andreoli L, Khamashta M, Tincani A. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. Autoimmun Rev. 2012;11(8):577-580.
32. Ortel TL. Thrombosis and the antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2005;462-468.
33. Crowther M, Crowther MA. Intensity of warfarin coagulation in the antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12(1):64-69.
34. Crowther MA. Anticoagulant therapy for the thrombotic complications of the antiphospholipid antibody syndrome. Thromb Res. 2004;114(5-6): 443-446.
35. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57(8):1487-1495.
36. Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood. 2013;122(5):817-824.
37. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12):1133-1138.
38. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3(5):848-853.
39. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685-696.
40. Devreese KM. Antiphospholipid antibody testing and standardization. Int J Lab Hematol. 2014; 36(3):352-363.